The estimated Net Worth of Blaine Templeman is at least $12.4 Million dollars as of 15 September 2020. Blaine Templeman owns over 12,369 units of Aduro BioTech stock worth over $12,008,726 and over the last 9 years Blaine sold ADRO stock worth over $393,249.
Sign up
Blaine Templeman ADRO stock SEC Form 4 insiders trading
Blaine has made over 16 trades of the Aduro BioTech stock since 2017, according to the Form 4 filled with the SEC. Most recently Blaine sold 12,369 units of ADRO stock worth $29,562 on 15 September 2020.
The largest trade Blaine's ever made was selling 12,878 units of Aduro BioTech stock on 13 September 2019 worth over $16,870. On average, Blaine trades about 2,455 units every 45 days since 2015. As of 15 September 2020 Blaine still owns at least 121,916 units of Aduro BioTech stock.
You can see the complete history of Blaine Templeman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Blaine Templeman's mailing address?
Blaine's mailing address filed with the SEC is C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY, CA, 94710.
Insiders trading at Aduro BioTech
Over the last 10 years, insiders at Aduro BioTech have traded over $5,295,750 worth of Aduro BioTech stock and bought 614,134 units worth $10,440,278 . The most active insiders traders include William Mariner Greenman, Stephen T Isaacs, and Thomas W. Dubensky. On average, Aduro BioTech executives and independent directors trade stock every 11 days with the average trade being worth of $2,189,064. The most recent stock trade was executed by Stephen T Isaacs on 15 September 2020, trading 32,481 units of ADRO stock currently worth $77,630.
What does Aduro BioTech do?
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
What does Aduro BioTech's logo look like?
Complete history of Blaine Templeman stock trades at Aduro BioTech
Aduro BioTech executives and stock owners
Aduro BioTech executives and other stock owners filed with the SEC include:
-
William Greenman,
Independent Director -
Ross Haghighat,
Independent Director -
Eric Bjerkholt,
Chief Financial Officer -
Noopur Liffick,
IR Contact Officer -
Dolca Thomas,
Director -
Michelle Griffin,
Director -
Jerel Davis,
Director -
Srinivas Akkaraju,
Director -
Alan Glicklich,
Chief Medical Officer -
Tom Frohlich,
Chief Business Officer -
Eric Dobmeier,
President, Chief Executive Officer, Director -
Thomas W. Dubensky,
Chief Scientific Officer -
Gregory W Schafer,
Chief Operating Officer -
Natalie Sacks,
Chief Medical Officer -
Frank Mccormick,
Director -
Gerald Chan,
Director -
Stephen T Isaacs,
President and CEO -
Stephanie Monaghan O Brien,
Director -
Stephen A Sherwin,
Director -
Dirk G. Brockstedt,
Sr. VP of Research and Dev. -
Frank Karbe,
Director -
Elsas Andrea Van,
Chief Scientific Officer -
David Henry Mack,
Director -
Celeste Ferber,
SVP, GC and Secretary -
Dimitry Sa Nuyten,
Chief Medical Officer -
Jennifer Lew,
Sr. Vice President of Finance -
Venture (Vi) Investments Lt...,
10% owner -
John E. And Lois A. Rogers,
10% owner -
Keen Ltd Ultimate,
10% owner -
Blaine Templeman,
Chief Legal Officer -
James H Welch,
See Remarks -
William G Kachioff,
Interim CFO